Literature DB >> 29703086

Pediatric Digital Necrosis Secondary to Dressing Application: A Case Series.

Kim A Bjorklund1, Dahlia M Rice2, Ashley N Amalfi2.   

Abstract

BACKGROUND: Pediatric digital necrosis resulting in revision amputation is a devastating outcome following digital dressing application.
METHODS: We report a series of 4 pediatric patients (age: 21 months-11 years) who presented for surgical consultation related to digital ischemia and irreversible necrosis following the application of Coban digital dressings. A review of the literature demonstrated that such injuries had not previously been described.
RESULTS: In our case series, Coban dressing was utilized as a deterrent for thumb sucking, fingertip tuft fractures with nail bed lacerations, and a phalanx fracture secondary to crush injury. All 4 children suffered digital necrosis secondary to Coban dressings and ultimately required revision amputation.
CONCLUSIONS: We discuss risks factors, application practices, and strategies to minimize complications with digital dressings in the pediatric population with the intent of creating awareness among hand surgeons to help promote safe practices and improve patient outcomes.

Entities:  

Keywords:  digital necrosis; finger dressings; pediatric

Mesh:

Year:  2018        PMID: 29703086      PMCID: PMC6081791          DOI: 10.1177/1558944718772387

Source DB:  PubMed          Journal:  Hand (N Y)        ISSN: 1558-9447


  3 in total

1.  Analysis of pressure achieved by various materials used for pressure dressings.

Authors:  S L Smith; J M Belmont; J M Casparian
Journal:  Dermatol Surg       Date:  1999-12       Impact factor: 3.398

2.  Preventing tourniquet effect when dressing finger wounds in children.

Authors:  Raymond G Hart; Thomas W Wolff; William L O'Neill
Journal:  Am J Emerg Med       Date:  2004-11       Impact factor: 2.469

3.  Dressed to kill: pressure necrosis secondary to finger dressing.

Authors:  Adel Fattah
Journal:  J Plast Reconstr Aesthet Surg       Date:  2006       Impact factor: 2.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.